MemoBoost

Company Overview

Snapshot

Founded in March 2016 by Prof. Edi Barkai, MemoBoost operates with 1–10 employees. The company has secured funding across one disclosed round from one investor. A significant milestone for MemoBoost was the development of a new drug treatment approach aimed at inhibiting the onset of dementia in March 2016.

Business overview

MemoBoost is a Health Tech & Life Sciences company focused on developing a pioneering drug treatment to inhibit the onset of dementia. The company's core technology is based on research into the scientific foundations of learning and memory in the brain, specifically targeting a receptor in the mGluR family to enhance cognitive function. MemoBoost operates in the Pharmaceuticals sector, serving global markets with its drug discovery and development efforts.

Company Intelligence Q&A

What is MemoBoost's primary focus?

MemoBoost is focused on developing a drug treatment designed to inhibit the onset of dementia, leveraging research into the neurobiology of learning and memory.

Who founded MemoBoost?

MemoBoost was founded by Prof. Edi Barkai, who also leads the Laboratory for Neurobiology of Learning and Memory at the University of Haifa.

When was MemoBoost founded?

MemoBoost was founded in March 2016.

What is the status of MemoBoost's operations?

MemoBoost ceased to operate in May 2024.

What significant technology development has MemoBoost achieved?

In March 2016, MemoBoost developed a new drug treatment approach aimed at inhibiting the onset of dementia, focusing on enhancing learning through a specific brain receptor.